Joe Dennis
- BRCA gene mutations in cancer
- Genetic Associations and Epidemiology
- Nutrition, Genetics, and Disease
- Ovarian cancer diagnosis and treatment
- Genetic factors in colorectal cancer
- Cancer Genomics and Diagnostics
- Cancer-related molecular mechanisms research
- Global Cancer Incidence and Screening
- Bioinformatics and Genomic Networks
- Genomics and Chromatin Dynamics
- Epigenetics and DNA Methylation
- Genomic variations and chromosomal abnormalities
- RNA modifications and cancer
- RNA Research and Splicing
- Genomics and Rare Diseases
- Cancer Risks and Factors
- Molecular Biology Techniques and Applications
- DNA Repair Mechanisms
- Colorectal Cancer Screening and Detection
- Gene expression and cancer classification
- Endometrial and Cervical Cancer Treatments
- AI in cancer detection
- Radiomics and Machine Learning in Medical Imaging
- Estrogen and related hormone effects
- Digital Radiography and Breast Imaging
University of Cambridge
2016-2025
Weatherford College
2025
Ofwat
2024
University of Wisconsin–Madison
2022
Sorbonne Université
2022
Cancer Research Center
2015-2021
University of Manchester
2021
St Mary's Hospital
2021
Edinburgh Cancer Research
2021
MRC Epidemiology Unit
2014-2020
Stratification of women according to their risk breast cancer based on polygenic scores (PRSs) could improve screening and prevention strategies. Our aim was develop PRSs, optimized for prediction estrogen receptor (ER)-specific disease, from the largest available genome-wide association dataset empirically validate PRSs in prospective studies. The development comprised 94,075 case subjects 75,017 control European ancestry 69 studies, divided into training validation sets. Samples were...
Background Defective cellular transport processes can lead to aberrant accumulation of trace elements, iron, small molecules and hormones in the cell, which turn may promote formation reactive oxygen species, promoting DNA damage expression key regulatory cancer genes. As uncontrolled proliferation are hallmarks cancer, including epithelial ovarian (EOC), we hypothesized that inherited variation genes contributes EOC risk. Methods In total, samples were obtained from 14,525 case subjects...
Genetic testing for breast cancer susceptibility is widely used, but many genes, evidence of an association with weak, underlying risk estimates are imprecise, and reliable subtype-specific lacking.
Common variation on 14q24.1, close to RAD51B, has been associated with breast cancer: rs999737 and rs2588809 the risk of female cancer rs1314913 male cancer. The aim this study was investigate role RAD51B variants in predisposition, particularly context familial Finland. We sequenced coding region 168 Finnish patients from Helsinki for identification possible recurrent founder mutations. In addition, we studied known rs999737, rs2588809, SNPs haplotypes 44,791 cases 43,583 controls 40...
Genetic variations, such as single nucleotide polymorphisms (SNPs) in microRNAs (miRNA) or the miRNA binding sites may affect dependent gene expression regulation, which has been implicated various cancers, including breast cancer, and alter individual susceptibility to cancer. We investigated associations between related SNPs cancer risk. First we evaluated 2,196 a case-control study combining nine genome wide association studies (GWAS). Second, further 42 with suggestive evidence for using...
Data for multiple common susceptibility alleles breast cancer may be combined to identify women at different levels of risk. Such stratification could guide preventive and screening strategies. However, empirical evidence genetic risk is lacking. We investigated the value using 77 cancer-associated single nucleotide polymorphisms (SNPs) stratification, in a study 33 673 cases 381 control European origin. tested all possible pair-wise multiplicative interactions constructed 77-SNP polygenic...
BRCA1-associated breast and ovarian cancer risks can be modified by common genetic variants. To identify further risk-modifying loci, we performed a multi-stage GWAS of 11,705 BRCA1 carriers (of whom 5,920 were diagnosed with 1,839 cancer), replication in an additional sample 2,646 carriers. We identified novel risk modifier locus at 1q32 for (rs2290854, P = 2.7×10−8, HR 1.14, 95% CI: 1.09–1.20). In addition, two loci: 17q21.31 (rs17631303, 1.4×10−8, 1.27, 1.17–1.38) 4q32.3 (rs4691139,...